Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) is expected to post its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect Oruka Therapeutics to post earnings of ($0.68) per share for the quarter.
Oruka Therapeutics Stock Performance
Shares of NASDAQ:ORKA opened at $11.02 on Friday. The firm has a market cap of $385.70 million, a PE ratio of -1.76 and a beta of 0.77. The stock's fifty day simple moving average is $15.62. Oruka Therapeutics has a 1-year low of $10.61 and a 1-year high of $53.88.
Analyst Upgrades and Downgrades
A number of brokerages have commented on ORKA. Wedbush restated an "outperform" rating and set a $40.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, November 19th. Wolfe Research began coverage on shares of Oruka Therapeutics in a research report on Tuesday, February 4th. They set an "outperform" rating and a $20.00 price objective for the company. Finally, HC Wainwright restated a "buy" rating and set a $45.00 price objective on shares of Oruka Therapeutics in a research report on Friday, February 7th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $39.86.
Check Out Our Latest Analysis on ORKA
Oruka Therapeutics Company Profile
(
Get Free Report)
Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Oruka Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oruka Therapeutics wasn't on the list.
While Oruka Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
